发明名称 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
摘要 <p>Chimeric antibody (A), derived from the monoclonal antibody P3, which recognizes N-glycosylated gangliosides and is produced by hybridoma ECACC 94113026, is new. Chimeric antibody (A), derived from the monoclonal antibody P3, which recognizes N-glycosylated gangliosides and is produced by hybridoma ECACC 94113026, has the following complementarity determining regions (CDR); for heavy chain: CDR1 (RYSVH); CDR2 (MIWGGGSTDYNSALKS) and CDR3 (SGVREGRAQAWFAY), and for the light chain: CDR1 (KASQDVSTAVA); CDR2 (SASYRYT) and CDR3 (QQHYSTPWT). Independent claims are also included for the following: (1) cell lines that produce (A); (2) chimeric monoclonal antibody (A') derived from the monoclonal antibody 1E10, which recognizes P3 and is produced by ECACC 97112901, having the CDRs: heavy chain: CDR1 (SYDIN); CDR2 (WIFPGDGSTKYNEKFKG) and CDR3 (EDYYDNSYYFDY), and light chain: CDR1 (RASQDISNYLN), CDR2 (YTSRLHSG), and CDR3 (QQGNTHPWT); and (3) cell lines that produce (A'). ACTIVITY : Cytostatic. No relevant biological data given. MECHANISM OF ACTION : Induction of a specific immune response. No relevant biological data given.</p>
申请公布号 KR100919617(B1) 申请公布日期 2009.09.29
申请号 KR20087019420 申请日期 2008.08.07
申请人 发明人
分类号 C07K16/18;C12N15/09;A61K31/7032;A61K31/739;A61K39/00;A61K39/395;A61P35/00;A61P35/04;A61P37/00;A61P37/04;A61P43/00;C07K16/00;C07K16/30;C07K16/42;C07K16/46;C12N1/15;C12N1/19;C12N1/21;C12N5/10;C12N5/20;C12P21/08 主分类号 C07K16/18
代理机构 代理人
主权项
地址